Literature DB >> 29782819

Analytical performance of an immunoassay to measure proenkephalin.

Leslie J Donato1, Jeffrey W Meeusen2, John C Lieske2, Deborah Bergmann3, Andrea Sparwaßer3, Allan S Jaffe4.   

Abstract

BACKGROUND: Endogenous opioids, enkephalins, are known to increase with acute kidney injury. Since the mature pentapeptides are unstable, we evaluated the performance of an assay that measures proenkephalin 119-159 (PENK), a stable peptide formed concomitantly with mature enkephalins.
METHODS: PENK assay performance was evaluated on two microtiterplate/chemiluminescence sandwich immunoassay formats that required 18 or 1 h incubation times. PENK concentration was measured in plasma from healthy individuals to establish a reference interval and in patients with varied levels of kidney function and comorbidities to assess the association with measured glomerular filtration rate (mGFR) using iothalamate clearance.
RESULTS: Assay performance characteristics in plasma were similar between the assay formats. Limit of quantitation was 26.0 pmol/L (CV = 20%) for the 1 h assay and 17.3 pmol/L (CV = 3%) for the 18 h assay. Measurable ranges were 26-1540 pmol/L (1 h assay) and 18-2300 pmol/L (18 h assay). PENK concentrations are stable in plasma stored ambient to 10 days, refrigerated to at least 15 days, and frozen to at least 90 days. Results were comparable in paired SST serum and EDTA plasma. Age and sex were not associated with PENK concentrations in healthy individuals (reference interval: 36-97.5 pmol/L). Plasma PENK concentration correlated with mGFR. In a multivariate model PENK concentration, age, sex and transplant status were significant predictors of mGFR, and 49% of predicted GFR values fell within 30% of the mGFR.
CONCLUSIONS: Both assay formats are accurate and precise for measuring clinically relevant PENK concentrations. The association of PENK concentration with mGFR is influenced by gender, age, and history of kidney transplantation. Future studies will determine if blood PENK can be used clinically to estimate GFR and/or detect AKI.
Copyright © 2018 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Assay validation; Biomarkers; Enkephalin; Pro-enkephalin; Proenkephalin; penKid

Mesh:

Substances:

Year:  2018        PMID: 29782819     DOI: 10.1016/j.clinbiochem.2018.05.010

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  7 in total

1.  Role of proenkephalin in the diagnosis of severe and subclinical acute kidney injury during the perioperative period of liver transplantation.

Authors:  Camila Lima; Daniella Lacerda Gorab; Carol Ribeiro Fernandes; Etienne Macedo
Journal:  Pract Lab Med       Date:  2022-05-06

2.  Advances in laboratory detection of acute kidney injury.

Authors:  Faeq Husain-Syed; Thiago Reis; Kianoush Kashani; Claudio Ronco
Journal:  Pract Lab Med       Date:  2022-06-02

3.  Neprilysin inhibition does not alter dynamic of proenkephalin-A 119-159 and pro-substance P in heart failure.

Authors:  Henrike Arfsten; Georg Goliasch; Philipp E Bartko; Suriya Prausmüller; Georg Spinka; Anna Cho; Johannes Novak; Julia Mascherbauer; Helmuth Haslacher; Guido Strunk; Martin Hülsmann; Noemi Pavo
Journal:  ESC Heart Fail       Date:  2021-03-20

4.  Proenkephalin and the risk of new-onset heart failure: data from prevention of renal and vascular end-stage disease.

Authors:  Johanna E Emmens; Jozine M Ter Maaten; Frank P Brouwers; Lyanne M Kieneker; Kevin Damman; Oliver Hartmann; Janin Schulte; Stephan J L Bakker; Rudolf A de Boer; Adriaan A Voors
Journal:  Clin Cardiol       Date:  2021-10-30       Impact factor: 2.882

5.  Plasma proenkephalin A 119-159 on intensive care unit admission is a predictor of organ failure and 30-day mortality.

Authors:  Attila Frigyesi; Lisa Boström; Maria Lengquist; Patrik Johnsson; Oscar H M Lundberg; Martin Spångfors; Martin Annborn; Tobias Cronberg; Niklas Nielsen; Helena Levin; Hans Friberg
Journal:  Intensive Care Med Exp       Date:  2021-07-19

6.  Proenkephalin Predicts Organ Failure, Renal Replacement Therapy, and Mortality in Patients With Sepsis.

Authors:  Hanah Kim; Mina Hur; Joachim Struck; Andreas Bergmann; Salvatore Di Somma
Journal:  Ann Lab Med       Date:  2020-06-17       Impact factor: 3.464

7.  Proenkephalin Compared to Conventional Methods to Assess Kidney Function in Critically Ill Sepsis Patients.

Authors:  Remi Beunders; Roger van Groenendael; Guus P Leijte; Matthijs Kox; Peter Pickkers
Journal:  Shock       Date:  2020-09       Impact factor: 3.533

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.